Summary
131.00 4.20(3.31%)10/04/2024
Glaukos Corporation (GKOS)
Glaukos Corporation (GKOS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 3.31 | 2.13 | 0.20 | 7.58 | 39.18 | 89.17 | 116.71 | 5,141.82 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 131.00 | |
| Open | 128.86 | |
| High | 131.61 | |
| Low | 128.48 | |
| Volume | 309,704 | |
| Change | 4.20 | |
| Change % | 3.31 | |
| Avg Volume (20 Days) | 375,532 | |
| Volume/Avg Volume (20 Days) Ratio | 0.82 | |
| 52 Week Range | 59.22 - 136.61 | |
| Price vs 52 Week High | -4.11% | |
| Price vs 52 Week Low | 121.21% | |
| Range | 1.66 | |
| Gap Up/Down | 0.00 | |
Fundamentals | ||
| Market Capitalization (Mln) | 7,005 | |
| EBIDTA | 7,890,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 1.6400 | |
| WallStreet Target Price | 53.57 | |
| Book Value | 12.8250 | |
| Earnings Per Share | -0.8350 | |
| EPS Estimate Current Quarter | -0.2400 | |
| EPS Estimate Next Quarter | -0.2800 | |
| EPS Estimate Current Year | -0.8700 | |
| EPS Estimate Next Year | -1.5100 | |
| Diluted EPS (TTM) | -0.8350 | |
| Revenues | ||
| Profit Marging | -0.1305 | |
| Operating Marging (TTM) | -0.1578 | |
| Return on asset (TTM) | -0.0282 | |
| Return on equity (TTM) | -0.0608 | |
| Revenue TTM | 294,004,992 | |
| Revenue per share TTM | 6.3970 | |
| Quarterly Revenue Growth (YOY) | 0.1520 | |
| Quarterly Earnings Growth (YOY) | 18.9630 | |
| Gross Profit (TTM) | 157,952,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.2212 | |
| Revenue Enterprise Value | 6.4268 | |
| EBITDA Enterprise Value | 206.9783 | |
| Shares | ||
| Shares Outstanding | 46,890,200 | |
| Shares Float | 45,157,798 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 3.85 | |
| Institutions (%) | 96.89 | |
10/03 12:10 EST - zacks.com
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?
GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
Glaukos Stock Soars 59.2% Year to Date: What's Behind the Rally?
GKOS stock is being driven by strong product demand, international expansion and pipeline progress, which position it for long-term growth despite supply risks.
09/23 01:30 EST - globenewswire.com
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
Press Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including upfront and milestone payments plus royalties Glaukos to fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and in other retinal diseases Nicox focused on continued Phase 3 development of lead drug-candidate, NCX 470 September 23 rd , 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it has entered into an exclusive research and license option agreement with Glaukos Corporation for NCX 1728, Nicox's novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor. Glaukos is a US ophthalmic pharmaceutical and medical device company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement
Press Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including upfront and milestone payments plus royalties Glaukos to fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and in other retinal diseases Nicox focused on continued Phase 3 development of lead drug-candidate, NCX 470 September 23 rd , 2024 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that it has entered into an exclusive research and license option agreement with Glaukos Corporation for NCX 1728, Nicox's novel nitric oxide (NO)-donating phosphodiesterase-5 (PDE5) inhibitor. Glaukos is a US ophthalmic pharmaceutical and medical device company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
09/11 09:32 EST - zacks.com
Glaukos Stocks Rides on Strong Product Demand Amid Competition
GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Glaukos Stocks Rides on Strong Product Demand Amid Competition
GKOS continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
09/09 14:40 EST - zacks.com
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.
08/22 14:20 EST - zacks.com
Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) Gains 63.5% YTD: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
08/02 20:01 EST - zacks.com
Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Glaukos (GKOS) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
08/01 08:35 EST - zacks.com
Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales
Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.
Glaukos (GKOS) Q2 Earnings In Line, Glaucoma Drives Sales
Glaukos' (GKOS) second-quarter 2024 results showcase growth in revenues on the back of strong adoption of its glaucoma products like iStent and iDose TR. Loss at the operating level raises concern.
07/31 20:57 EST - seekingalpha.com
Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS ) Q2 2024 Results Conference Call July 31, 2024 4:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Larry Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Harrison Parsons - Stephens Margaret Kaczor - William Blair Joanne Wuensch - Citibank Rich Newitter - Truist Securities Steve Lichtman - Oppenheimer Anthony Petrone - Mizuho Operator Hello, and welcome to Glaukos Corporation's Second Quarter 2024 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today, are available at www.glaukos.com.
Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript
Glaukos Corporation (NYSE:GKOS ) Q2 2024 Results Conference Call July 31, 2024 4:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Larry Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Harrison Parsons - Stephens Margaret Kaczor - William Blair Joanne Wuensch - Citibank Rich Newitter - Truist Securities Steve Lichtman - Oppenheimer Anthony Petrone - Mizuho Operator Hello, and welcome to Glaukos Corporation's Second Quarter 2024 Financial Results Conference Call. Copies of the company's press release and quarterly summary document, both issued after the market closed today, are available at www.glaukos.com.
07/31 19:20 EST - zacks.com
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.52 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.52 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago.
07/31 14:30 EST - investorplace.com
7 Leading MedTech Stocks for Next-Gen Health Solutions
While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.
7 Leading MedTech Stocks for Next-Gen Health Solutions
While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.
07/30 14:35 EST - zacks.com
Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.
Will These 4 MedTech Stocks Beat Forecasts This Earnings Season?
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how COR, XRAY, GEHC and GKOS are placed ahead of their earnings release.
07/24 11:07 EST - zacks.com
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
07/22 12:30 EST - zacks.com
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
07/10 09:05 EST - benzinga.com
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
07/03 08:40 EST - zacks.com
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
06/27 13:50 EST - zacks.com
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
06/27 04:20 EST - zacks.com
Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar?
Glaukos (GKOS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar?
Glaukos (GKOS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
06/14 07:00 EST - businesswire.com
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 2.75% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”). Pursuant to these Exchange Agreements, the company agreed, subject to customary closing conditions, to repurchase an aggregate of $230 million pri.
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 2.75% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”). Pursuant to these Exchange Agreements, the company agreed, subject to customary closing conditions, to repurchase an aggregate of $230 million pri.
06/05 13:16 EST - zacks.com
Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.